SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
3D Paper Cut Pair of Lung dotted with yellow tumor bacteria infection spread across on a blue background with no text. Yellow dots as virus infection in the lungs. Vector Illustration.
Lung cancer
Akeso, Summit’s PD-1/VEGF Blocker ‘Firmly’ Beats Expectations With Encouraging Survival Data
Ivonescimab’s progression-free survival data in non-small cell lung cancer bode well for an upcoming overall survival readout, according to Truist analysts, who noted that “OS is likely to be statistically significant” in favor of the PD-1/VEGF bispecific.
October 20, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration showing hands holding arrow that goes up and down a few times and ends up in upward direction
Mergers & acquisitions
Rumors of Eli Lilly Buyout Send Nektar’s Shares Spiking
Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma’s partnership with Nektar over atopic dermatitis therapy rezpeg.
October 20, 2025
 · 
2 min read
 · 
Tristan Manalac
searching for the virus cure medical pills in pattern on vibrant background
Approvals
Novo Secures Cardiovascular Expansion for Semaglutide Pill
Rybelsus can now be used as a primary or secondary prevention pill to lower the risk of major adverse cardiovascular events in at-risk patients with type 2 diabetes.
October 20, 2025
 · 
2 min read
 · 
Tristan Manalac
Scanner on blue human eye
Rare diseases
Glaukos Notches FDA Nod for Rare Eye Disorder Keratoconus
Glaukos’ Epioxa allows cross-linking therapy for keratoconus without requiring an incision. The biotech expects to launch the drug early next year.
October 20, 2025
 · 
1 min read
 · 
Tristan Manalac
Pictured: Cancer patient in bed looking out window
Opinion
Counteracting Complacency in Multiple Myeloma—We’re Not There Yet
Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but the fight against the disease must continue.
October 20, 2025
 · 
6 min read
 · 
Michael Andreini
business symbol for teamwork as abstract symbol
FDA
FDA’s Lost Leaders: Where Are They Now?
After a chaotic year that has seen the attrition of over half the FDA’s senior leadership, many of these individuals have landed new roles—at Eli Lilly, Pfizer, Iovance and more. The FDA’s loss, it seems, is largely the pharmaceutical industry’s gain.
October 20, 2025
 · 
8 min read
 · 
Heather McKenzie
background, no people
Drug pricing
Novo, Lilly Shares Drop as Trump Promises $150 Ozempic
CMS Administrator Mehmet Oz clarified that a deal has not yet been sealed with the manufacturer of semaglutide, Novo Nordisk, or any other GLP-1 drugmaker.
October 17, 2025
 · 
3 min read
 · 
Annalee Armstrong
Pleasanton, CA, USA - Feb 21, 2024: Exterior view of the headquarters of Roche Molecular Diagnostics (RMD) in Pleasanton, California. F. Hoffmann-La Roche AG is a Swiss pharmaceutical company.
Antibody-drug conjugate (ADC)
Roche Inks Another China ADC Pact With $1.5B Hansoh Bet
Roche will gain worldwide rights outside of the Greater China region to Hansoh’s HS-20110, an antibody-drug conjugate in early-stage development for colorectal cancer.
October 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Holds tickets in hand, isolated on white background. Vector flat. stock illustration
Regulatory
FDA Hands Out First Commissioner’s Priority Vouchers to Regeneron, Sanofi, Disc, Others
The Commissioner’s National Priority Voucher awards companies that align with specific national priorities—such as boosting domestic manufacturing and lowering drug prices—with faster reviews and more frequent interactions with the FDA.
October 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS